Why the study?
Do disopyramide and nifekalant normalize QT interval and effective refractory period in a patient with short QT syndrome?
Do disopyramide and nifekalant normalize QT interval and effective refractory period in a patient with short QT syndrome?
Disopyramide and nifekalant normalized QT interval and ERP in a patient with short QT syndrome, suggesting their feasibility as pharmacological treatments.
Answers are grounded in this paper and cite their sources.
May support disopyramide and nifekalant in short QT syndrome; hypothesis-generating and requires prospective confirmation.
We assessed several pharmacological effects on electrocardiogram parameters and effective refractory period (ERP) in a patient with a short QT syndrome (SQTS). Pharmacological challenge tests revealed that disopyramide and selective I(kr) blocker, nifekalant normalized QT interval, and ERP of the atrial and ventricular myocardium. This study suggested that disopyramide and nifekalant should be feasible for the drug treatment of the SQTS. Moreover, QT interval was paradoxically prolonged at higher heart rates induced with isoproterenol infusion or an exercise test, although the mechanism of this QT prolongation remains to be investigated.
No takes yet. Share an insight, caveat, or question.
Mizobuchi et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: